Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289299 · ClinicalTrials.gov registry record · Phase 2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
A Phase 2 study of Smoldering Multiple Myeloma, sponsored by International Myeloma Foundation.
- Active
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 10
- Study locations
NCT03289299: Active Phase 2 study of Smoldering Multiple Myeloma, sponsored by International Myeloma Foundation.
NCT03289299 is a Phase 2 study of Smoldering Multiple Myeloma that is active but no longer recruiting, run by International Myeloma Foundation. The registered enrollment target is 87 participants, below the 795-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289299, a Phase 2 study of Smoldering Multiple Myeloma, is active but no longer recruiting, sponsored by International Myeloma Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.
Primary Outcome
A confirmed sCR on 2 consecutive evaluations at any time during the course of treatment.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Carfilzomib
Study Locations (10)
Florida
- Moffitt Cancer Center - Tampa
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Kansas
- University of Kansas Cancer Center - Westwood
Maryland
- University of Maryland Medical Center - Baltimore
Minnesota
- Mayo Clinic - Rochester
New York
- Weill Cornell Medicine - New York
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2018-05-25 |
| Est. Completion | 2031-11-15 |
| Phase | Phase 2 |
What the registry record for NCT03289299 still lists
NCT03289299 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 795-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT03289299 lists 10 locations in 10 states (Florida, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT03289299 about?
NCT03289299 is a clinical study titled "Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant". This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.
What is the current status of trial NCT03289299?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2018-05-25. Estimated completion is 2031-11-15.
What conditions does trial NCT03289299 study?
This clinical trial studies the following conditions: Smoldering Multiple Myeloma.
What interventions are being tested in trial NCT03289299?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT03289299?
This trial is sponsored by International Myeloma Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03289299 being conducted?
This trial has 10 study locations across Florida, Illinois, Indiana, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03289299's enrollment target sits among peer trials
87 12th of 20 higher than 9 of 20 other Smoldering Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
RECRUITING · Phase 2
-
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
ACTIVE NOT RECRUITING · Phase 2
-
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI